Array BioPharma appoints Jason Haddock CFO

Thursday July 28, 2016 0 comments Tags: Boulder, Array BioPharma, Ron Squarer, Jason Haddock, David Horin

BOULDER -- Array BioPharma  (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, announced it has appointed Jason Haddock as Chief Financial Officer.Array_Bio_logoUSE

Haddock's appointment was immediately effective and he will be replacing David Horin, who had been acting as Array's interim CFO. Horin will continue to provide services to Array on a consulting basis, the company said.

Haddock has more than 15 years of financial and operational experience in the biopharmaceutical industry. 

He held leadership positions of increasing responsibility at Bristol-Myers Squibb, a global pharmaceutical company with a strong focus on immuno-oncology therapies, in a variety of accounting, planning, commercial, analytical and business development capacities over more than 13 years through 2015.

Haddock most recently served as CFO and Chief Operating Officer of BERG Health, an oncology-focused research, diagnostics and development company, where he oversaw the implementation of financial and operational processes, procedures and policies to transform and scale the company's practices as it planned for growth and corporate evolution.

"We are pleased to welcome Jason to Array's executive team during a pivotal time for our company," said Ron Squarer, Array's CEO. "He brings strong financial and operational expertise across many therapeutic areas and in commercial, medical and operational functions, and is well-versed on the nuances and challenges in the pharmaceutical landscape.

“We look forward to having Jason in this role as we continue to plan for commercialization of two wholly-owned drugs in the US."

Array said it is approaching several significant near-term milestones, including top-line results from the COLUMBUS Phase 3 pivotal trial and a projected regulatory filing of binimetinib (MEK inhibitor) in combination with encorafenib (BRAF inhibitor) in BRAF-mutant melanoma.

"I am excited about the opportunity to join Array and look forward to leveraging my industry experience to help strengthen the Company's financial and operational performance," said Haddock.

"Array is well-positioned to capitalize on its robust drug pipeline and I am confident we can successfully execute on its plan to drive value for shareholders."

Haddock earned his undergraduate degree in accounting from Illinois State University and is a Certified Management Accountant. He holds an MBA from Washington University in St. Louis where he completed the Executive Program.